Depict Bio LLC Company Profile

Background

Overview

Depict Bio LLC is a biotechnology company specializing in precision medicine, focusing on the development of targeted therapies for progressive, polygenic diseases, with an initial emphasis on ophthalmology. The company aims to identify genetic and molecular drivers of disease progression to create therapies for patients in urgent need.

Mission and Vision

Depict Bio's mission is to transform drug development for complex diseases by leveraging comprehensive genetic and clinical data to develop precise and effective treatments. The vision is to deliver a new generation of precision medicines that treat and ultimately cure age-related blindness.

Primary Area of Focus

The company's primary focus is on ophthalmology, particularly age-related eye diseases such as age-related macular degeneration (AMD). By integrating genetics with longitudinal clinical and imaging data, Depict Bio aims to reclassify complex diseases into genetically defined subtypes, unlocking novel therapeutic targets and optimizing patient selection for clinical trials.

Industry Significance

Depict Bio is significant in the biotechnology industry for its innovative approach to precision medicine, combining genomics, deep clinical data, and AI-driven modeling to discover and develop therapies that are more precise and effective. This approach has the potential to revolutionize the treatment of progressive, polygenic diseases, starting with ophthalmology.

Key Strategic Focus

Core Objectives

Identify genetic and molecular drivers of disease progression.

Develop targeted therapies for progressive, polygenic diseases.

Optimize patient selection for clinical trials through deep phenotyping.

Specific Areas of Specialization

Genetic and molecular profiling of diseases.

Integration of genetics with clinical and imaging data.

Development of AI-driven models for drug discovery.

Key Technologies Utilized

Genomic sequencing and analysis.

Longitudinal clinical and imaging data integration.

AI and machine learning algorithms for data modeling.

Primary Markets or Conditions Targeted

Age-related macular degeneration (AMD).

Other progressive, polygenic diseases.

Financials and Funding

Funding History

Total Funds Raised: $19.93 million.

Recent Funding Rounds:

Series A: $17 million raised in February 2022, led by Tiger Global, with participation from Initialized Capital, EQT Ventures, and others.

Notable Investors

Tiger Global

Initialized Capital

EQT Ventures

Other undisclosed investors

Intended Utilization of Capital

The capital raised is intended to support product development and expansion into European and U.S. markets.

Pipeline Development

Key Pipeline Candidates

CTX114: A program advancing toward clinical trials, designed to slow or prevent vision loss in AMD patients.

CTX203: Another program progressing toward clinical trials, aimed at treating age-related blindness.

Stages of Clinical Trials or Product Development

Both CTX114 and CTX203 are in the preclinical stage, with plans to enter clinical trials in the near future.

Target Conditions

Age-related macular degeneration (AMD).

Other age-related eye diseases.

Relevant Timelines for Anticipated Milestones

Specific timelines for clinical trial initiation and subsequent milestones have not been publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

Comprehensive genomic sequencing and analysis platforms.

Integrated clinical and imaging data systems.

AI and machine learning models for data interpretation and drug discovery.

Significant Scientific Methods

Deep phenotyping combining genetic, clinical, and imaging data.

AI-driven modeling for identifying therapeutic targets and patient stratification.

Leadership Team

Key Executive Profiles

Fesarius Therapeutics: Partner company associated with Depict Bio.

Leadership Changes

Specific details regarding recent leadership changes or appointments within Depict Bio have not been publicly disclosed.

Competitor Profile

Market Insights and Dynamics

The precision medicine market, particularly in ophthalmology, is experiencing significant growth, driven by advancements in genomics and AI technologies.

There is an increasing demand for targeted therapies for progressive, polygenic diseases, presenting opportunities for companies like Depict Bio.

Competitor Analysis

Generate Biomedicines, Inc.: Focuses on designing novel proteins for therapeutic applications.

Schrödinger, Inc.: Specializes in computational drug discovery and materials science.

Recursion Pharmaceuticals, Inc.: Utilizes AI and machine learning for drug discovery.

Relay Therapeutics, Inc.: Focuses on precision medicine through dynamic protein analysis.

Exscientia Limited: Applies AI to drug discovery and design.

Strategic Collaborations and Partnerships

Depict Bio has partnered with over 150 ophthalmology clinics to integrate genetics with longitudinal clinical and imaging data, enhancing its research capabilities.

Operational Insights

Depict Bio differentiates itself through its deep phenotyping approach, combining extensive genetic and clinical data with AI-driven modeling to identify novel therapeutic targets and optimize patient selection for clinical trials.

Strategic Opportunities and Future Directions